Bristol-Myers Squibb Expects Solid Q2 Ahead of Bigger H2, RBC Says

Bristol-Myers Squibb (BMY) is expected to boast a "solid" Q2 in line with expectations on revenue and earnings ahead of what is expected to be a "pivotal" H2, RBC Capital Markets said in note Friday. RBC noted a lack of "idiosyncrasies" in the company's Q2. "It's encouraging to see Bristol-Myers Squibb continue to execute across the commercial portfolio," the note said. Investors remain focused on H2, with ahead of anticipated milestones for its Milvexian anti-stroke and Cobenfy Alzheimer's candidates, the note said. RBC had a sector perform rating, with a $60 price target.